Skip to main content

Market Overview

Bristol-Myers, Acceleron's Reblozyl Ok'd In Canada For MDS-Associated Anemia

  • Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia in myelodysplastic syndromes (MDS) patients with ring sideroblasts.
  • It is a low-risk subtype of blood cancer in which red blood cells contain a ring of excess iron.
  • The approval is limited to those who require regular red blood cell transfusion and have failed an erythropoietin-based therapy.
  • The treatment received FDA approval in April last year for the same indication. In Europe, the med was approved in June last year.
  • Price Action: BMY shares are down 0.50% at $59.69, and XLRN shares are down 3.21% at $126.65 on last check Tuesday.

Related Articles (BMY + XLRN)

View Comments and Join the Discussion!

Posted-In: AnemiaBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at